All physicians and laboratories are mandated to report measles to MHSs in the Netherlands. Each MHS records patient information in a national database, which includes information on age, postal code, date of symptoms, complications, hospitalization, and source of infection. Notifications of measles cases were used to assess medical costs and productivity losses (Technical Appendix). Information on additional serologic tests and extra vaccinations among health care workers in hospitals were obtained from a study on the implementation of measles guidelines for hospitals (Technical Appendix). Information about vaccinations of infants and older unvaccinated children in response to the outbreak was retrieved from the national immunization register. We interviewed staff at MHSs and the RIVM to assess the amount of personnel time related to outbreak response activities (Technical Appendix).

During the epidemic, 2,700 measles cases were reported, mostly among children 5–14 years of age (Table 1). In 329 patients, complications such as otitis media, pneumonia, and encephalitis developed. One child died from measles complications, and 181 patients were hospitalized. One patient with encephalitis spent 8 months in a rehabilitation clinic. Of patients who consulted a physician but were not hospitalized, 199 experienced complications, mostly otitis media (104 patients) or pneumonia (75 patients). Total estimated cost for direct health care was $1,255,718 (mean $465/case). An additional $365,885 ($136/case) was attributed to productivity losses and informal child care losses (Technical Appendix Table 1). In 2013, most (85%) responding hospitals in the Netherlands offered a serologic test to employees to ensure that they were sufficiently protected against measles (Technical Appendix). Employees identified as being at risk for measles infection were offered an MMR vaccination. On average, 80 serologic tests led to 63 vaccinations per hospital for a total estimated cost of $222,203 (Technical Appendix Table 2).

At the start of the outbreak, RIVM convened a national outbreak management team to discuss a strategy regarding targeted vaccination campaigns for infants living in communities with low vaccination coverage and for previously unvaccinated persons. A total of 6,652 infants received a complimentary MMR vaccination. Among children 18 months–19 years of age, 6,948 received an MMR vaccination during July 2013–March 2014. Costs for these vaccinations were $299,840. During this outbreak, the RIVM also coordinated outbreak control, conducted enhanced surveillance, and responded to extensive media attention (online Technical Appendix). Total costs for outbreak response activities by the RIVM were an estimated $698,280 ($259/case). In addition, we collected information from 6 MHSs that together had recorded more than half of all notified measles cases nationally. Their response activities included registration and processing of cases, vaccination activities, and advising of local authorities, professionals, and the general population (Technical Appendix). Total estimated costs for all MHSs was $1,852,470 ($686/case).

The MHSs incurred most of the costs of the outbreak, followed by costs for hospitalizations (Table 2). Costs of outbreak response activities by the RIVM were also considerable. Costs classified as other medical costs (i.e., consultations with general practitioners), productivity losses, and costs for vaccination campaigns were among the lowest (Table 2; Technical Appendix Table 3).

The measles outbreak occurring in the Netherlands during 2013–2014 was associated with substantial costs of ≈$4.7 million (€3.9 million), or 0.0042% of overall health care costs ($113 billion in 2013) in the Netherlands. The 2,700 reported measles cases during this outbreak resulted in an estimated $1,739 per case. Outbreak management costs were the primary cost, probably because of demands for expert advice, response to extensive media attention, registration of notified cases, and more surveillance activities than usual.

Despite being substantial, the outbreak costs in our study are underestimated. Because of data limitations, we were unable to estimate normal human immunoglobulin costs, patients’ traveling costs, or costs of vaccinations of adults or of long-term complications of disease. Also, reported cases in other countries have been linked to this outbreak, including Canada, United States, and Belgium; associated costs for cases exported to other countries are not included in our calculations. Furthermore, surveillance systems are affected by a degree of underreporting; therefore, uncertainty exists about the “true” economic costs of disease (10). In a previous measles outbreak in the Netherlands, the estimated true number of measles cases was ≈10 times the number of cases reported in the surveillance system (11). Moreover, only 47% of hospitalized cases in the previous outbreak were reported (12). Applying these data to our results, the estimated total outbreak costs would be ≈$0.9 million higher. Further research into the extent of underreporting in this outbreak is planned.

In Australia, the public health unit cost for responding to a single case of measles was $1,701 (7), a similar amount to our results. In the United States, costs of containing an outbreak were estimated at $6,180 per case. Additional US studies report that containment of a single imported measles case resulted in even higher costs per case (5,6). Explanations for the higher costs in the United States include more extensive contact tracing and higher medical care expenses.

The 2013–2014 measles outbreak posed considerable logistical challenges for MHS staff. Registration of reported cases contributed especially to the increased workload and costs created by this measles outbreak. To reduce this workload during a large outbreak, information considered to be critical for review could be collected for most patients, who usually recover within a few days or weeks, while more detailed information should continue to be collected for patients with complications or serious illness.

Measles substantially affects patients’ quality of life (13) and their ability to perform their usual daily activities. Complications resulting from measles, such as pneumonia, encephalitis, and subacute sclerosing panencephalitis, sometimes occur a few years after the illness (14). Complications from measles also affect quality of life and incur high financial costs, as shown in the extensive rehabilitation care needed by a patient with encephalitis that resulted from this outbreak. In the Netherlands, because religious arguments affect vaccination rates (15), elimination of measles will be challenging. Measles outbreaks are expected to continue to cause substantial effects from disease and economic costs. To prepare for new outbreaks, medical costs, productivity losses, and containment costs should be considered.